Medical news
of the North Caucasus
Scientific journal
Mass media registration certificate dated December 7, 2006.
Series ПИ #ФС 77-26521.
Federal service for surveillance over non-violation of the legislation in the sphere of mass communications and protection of cultural heritage.
ISSN 2073-8137

Site search

Correspondence address
310 Mira Street, Stavropol, Russia, 355017

+7 8652 352524; +7 8652 353229.

+7 8652 352524.


The genetic background of calcific aortic valve disease: retrospective study

[Internal diseases]
Elena Scheglova; Asiyat Laipanova; Madina Baikulova; Zarema Chotchayeva; Alexandr Yagoda; Olga Boeva;

We examined 108 patients with tricuspid aortic valve (AV) calcification (48.5 % males, mean age 72.5±7.5 years). Control group consisted of 92 patients with intact AV and comparable with the main group by sex, age and profile of cardiovascular disease. Diagnosis of calcific aortic valve disease was verified through multislice spiral computed tomography and echocardiography. Genotyping was carried out by polymerase chain reaction. Genetic polymorphisms were determined: Leu28Pro of the apolipoprotein E gene, Gln192Arg of the paraoxonase 1 gene, 8202A>G of matrix metalloproteinase type 9 gene, 536C>T of the tissue inhibitor of the matrix metalloproteinases type 1 gene, 138T>C and 7G>A of the matrix GLA-protein gene, 66T>G of the osteopontin gene and TagIC>T of the vitamin D receptor gene of apoE. It is established that the alleles 66G of osteopontin gene, 7A of matrix GLA-protein gene, as well as TagI T of vitamin D receptor gene are more common in patients with CAVD and showed association with this disease. The presence of the osteopontin gene and the 8202G allele of the 9 type matrix metalloproteinase gene in the genotype of the 66G allele indicates a risk of aortic stenosis
with an already available valvular calcification. The data presented open the new approaches to the early diagnosis and prevention of calcific aortic valve disease in the clinical practice and serve as a basis for future research.


1. Chumakova O. S., Selezneva N. D., Yevdokimova M. A.,Osmolovskaya V. S., Kochkina M. S., Aseycheva O. Yu., Minushkina L. O., Baklanova T. N., Talyzin P. A., Tereshchenko S. N., Dzhaiani N. A., Akatova Ye. V., Glezer M. G., Galyavich A. S., Zakirova V. B., Koziolova N. A., Polyanskaya Ye. A., Yagoda A. V., Boyeva O. I., Khorolets Ye. V., Shlyk S. V., Volkova E. G., Rodicheva O. A., Levashov S. Yu., Konstantinov V. O., Kalishevich N. B., Zateyshchikov D. A. Prognostic value of aortic stenosis in patients after exacerbation of ischemic heart disease. Kardiologiya. – Cardiology. 2011;51(1):23-28. (In Russ.).
2. Tipteva T. A., Chumakova O. S., Zateyshchikov D. A. Molecular-genetic actors, associated with aortic stenosis development. Rossysky kardiologichesky zhurnal. – Russ. J. Cardiol. 2015;10(126):99-106. (In Russ.). http://doi.org/10.15829/1560-4071-2015-10-99-106
3. Kutikhin A. G., Yuzhalin A. E., Brusina E. B., Ponasenko A. V., Golovkin A. S., Barbarash O. L. Genetic predisposition to calcific aortic stenosis and mitral annular calcification. Mol. Biol. Rep. 2014;41(9):5645-5663. http://doi.org/10.1007/s11033-014-3434-9
4. Shostak N. A., Karpova N. Yu., Rashid M. A., Kazakova T. V. Calcific aortic stenosis and osteoporosis: markers of bone metabolism and system calcium metabolism in eldery. Terapevtichesky arkhiv. –Therapeutic archive. 2007;79(9):45-49. (In Russ.).
5. Kienreich K., Grübler M., Tomaschitz A. Vitamin D, arterial hypertension and cerebrovascular disease. Indian. J. Med. Res. 2013;137:669-679.
6. Baeke F., Takiishi T., Korf H. Vitamin D: modulator of the immune system. Curr. Opin. Pharmacol. 2010;10(4):482-496. http://doi.org/10.1016/j.coph.2010.04.001
7. Bartley J. Vitamin D, innate immunity and upper respiratory tract infection. J. Laryngol. Otol. 2010;124(5):465-474. http://doi.org/10.1017/S0022215109992684
8. Valdivielso J. M., Fernandez E. Vitamin D receptor polymorphisms and diseases. Clinica Chimica Acta. 2006;357:1-12. http://doi.org/10.1016/j.cca.2006.02.016
9. O’Brien K. D. Epidemiology and genetics of calcific aortic valve disease. J. Investig. Med. 2007;55(6):284-291. http://doi.org/10.2310/6650.2007.00010
10. Adams J. S. Update in Vitamin D. J. Clin. Endocrinol. Metab. 2010;95:471-478. http://doi.org/10.1210/jc.2009-1773
11. Kahles F., Findeisen H. M., Bruemmer D. Osteopontin: A novel regulator at the cross roads of inflammation, obesity and diabetes. Mol. Metab. 2014;3:384-393. http://doi.org/10.1016/j.molmet.2014.03.004
12. Waller A. H., Sanchez-Ross M., Kaluski E. Osteopontin in cardiovascular disease: a potential therapeutic target. Cardiol. Rev. 2010;18:125-131. https://doi.org/10.3892/mmr.2013.1522
13. Yu P.-J., Skolnick A., Ferrari G. Correlation between plasma osteopontin levels and aortic valve calcification: Potential insights into the pathogenesis of aortic valve calcification and stenosis. Thorac. Cardiovasc. Surg. 2009;138:196-205. http://doi.org/10.1016/j.jtcvs.2008.10.045
14. Kim Y., Lee C. Haplotype analysis revealed a genetic influence of osteopontin on large artery atherosclerosis. J. Biomed. Sci. 2008;15:529-533. https://doi.org/10.1186/ar4129
15. Proudfoot D., Shanahan C. M. Molecular mechanisms mediating vascular calcification: role of matrix Gla protein. Nephrology (Carlton). 2006;11:455-461. http:// doi.org/10.1007/s11373-008-9240
16. Cassidy-Bushrow A. E., Bielak L. F., Levin A. M. Matrix GLA protein gene polymorphism is associated with increased coronary artery calcification progression. Arterioscler. Thromb. Vasc. Biol. 2013;33(3):645-651. http:// doi.org/10.1161/ATVBAHA.112.300491

Keywords: calcific aortic valve disease, aortic stenosis, genetic polymorphism, osteopontin, matrix Gla-protein, vitamin D receptor, metalloproteinase

Stavropol State Medical Academy
Pyatigorsk State Research Institute of Balneotherapeutics
Pyatigorsk State Pharmaceutical Academy